Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Integral Diagnostics Ltd. ( (AU:IDX) ) has issued an update.
Integral Diagnostics Ltd has disclosed a change in the interests of director Ian Kadish following the vesting of short-term incentive (STI) performance rights. On 22 December 2025, 34,233 STI performance rights vested into fully paid ordinary shares, increasing Kadish’s direct shareholding from 639,548 to 673,781 shares, while his STI performance rights balance decreased accordingly and his long-term incentive (LTI) performance rights holdings rose slightly due to adjustments. The transaction, undertaken for nil cash consideration, reflects the execution of the company’s incentive arrangements and further aligns the chief executive’s equity exposure with shareholder interests.
The most recent analyst rating on (AU:IDX) stock is a Sell with a A$2.10 price target. To see the full list of analyst forecasts on Integral Diagnostics Ltd. stock, see the AU:IDX Stock Forecast page.
More about Integral Diagnostics Ltd.
Integral Diagnostics Ltd is an Australian-based provider of medical imaging services, operating diagnostic imaging clinics that deliver radiology and related services to patients, referrers and healthcare providers across its markets.
Average Trading Volume: 979,263
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$898.8M
See more insights into IDX stock on TipRanks’ Stock Analysis page.